Cencora, Inc.
Cencora, Inc. COR Peers
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $291.17 | -1.41% | 56.4B | 33.73 | $8.63 | +0.74% |
| MCK | $705.45 | -3.06% | 88.3B | 27.42 | $25.74 | +0.40% |
| CAH | $161.98 | -1.47% | 38.6B | 25.33 | $6.39 | +1.25% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $74.48 | +0.00% | 9.1B | 23.20 | $3.21 | N/A |
| PBH | $80.18 | -0.17% | 4B | 18.69 | $4.29 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $20.59 | -3.79% | 1.3B | -12.95 | -$1.59 | N/A |
| OMI | $9.29 | -1.38% | 711M | -1.95 | -$4.76 | N/A |
| ZYXI | $2.69 | +1.13% | 81.3M | -11.21 | -$0.24 | N/A |
Stock Comparison
COR vs MCK Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, MCK has a market cap of 88.3B. Regarding current trading prices, COR is priced at $291.17, while MCK trades at $705.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas MCK's P/E ratio is 27.42. In terms of profitability, COR's ROE is +2.41%, compared to MCK's ROE of -1.33%. Regarding short-term risk, COR is less volatile compared to MCK. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs CAH Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, CAH has a market cap of 38.6B. Regarding current trading prices, COR is priced at $291.17, while CAH trades at $161.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas CAH's P/E ratio is 25.33. In terms of profitability, COR's ROE is +2.41%, compared to CAH's ROE of -0.50%. Regarding short-term risk, COR is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs ABC Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $291.17, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +2.41%, compared to ABC's ROE of +2.52%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs HSIC Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, HSIC has a market cap of 9.1B. Regarding current trading prices, COR is priced at $291.17, while HSIC trades at $74.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas HSIC's P/E ratio is 23.20. In terms of profitability, COR's ROE is +2.41%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs PBH Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, PBH has a market cap of 4B. Regarding current trading prices, COR is priced at $291.17, while PBH trades at $80.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas PBH's P/E ratio is 18.69. In terms of profitability, COR's ROE is +2.41%, compared to PBH's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs PDCO Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $291.17, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +2.41%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs GRDN Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, COR is priced at $291.17, while GRDN trades at $20.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas GRDN's P/E ratio is -12.95. In terms of profitability, COR's ROE is +2.41%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs OMI Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, OMI has a market cap of 711M. Regarding current trading prices, COR is priced at $291.17, while OMI trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas OMI's P/E ratio is -1.95. In terms of profitability, COR's ROE is +2.41%, compared to OMI's ROE of -0.51%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs ZYXI Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, ZYXI has a market cap of 81.3M. Regarding current trading prices, COR is priced at $291.17, while ZYXI trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas ZYXI's P/E ratio is -11.21. In terms of profitability, COR's ROE is +2.41%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, COR is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs WGRX Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, WGRX has a market cap of 66.7M. Regarding current trading prices, COR is priced at $291.17, while WGRX trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas WGRX's P/E ratio is -1.21. In terms of profitability, COR's ROE is +2.41%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs GEG Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, GEG has a market cap of 58.1M. Regarding current trading prices, COR is priced at $291.17, while GEG trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas GEG's P/E ratio is -41.60. In terms of profitability, COR's ROE is +2.41%, compared to GEG's ROE of -0.02%. Regarding short-term risk, COR is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for COR.
COR vs HX Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $291.17, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +2.41%, compared to HX's ROE of -0.04%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs RDGT Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, RDGT has a market cap of 6.5M. Regarding current trading prices, COR is priced at $291.17, while RDGT trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas RDGT's P/E ratio is -0.34. In terms of profitability, COR's ROE is +2.41%, compared to RDGT's ROE of -0.36%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.
COR vs CVET Comparison
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 56.4B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $291.17, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 33.73, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +2.41%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.